Condition
OIC
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Not Yet Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07534995Phase 3Not Yet RecruitingPrimary
A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Trial
NCT04930237WithdrawnPrimary
RELISTOR's Effects on Opioid-Induced Constipation
NCT01702194Phase 1CompletedPrimary
TD-1211 IV/Oral Mass Balance Study
NCT01418092Phase 2CompletedPrimary
ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
Showing all 4 trials